Literature DB >> 16543594

Lung cancer perfusion at multi-detector row CT: reproducibility of whole tumor quantitative measurements.

Quan-Sing Ng1, Vicky Goh, Heinz Fichte, Ernst Klotz, Pat Fernie, Michele I Saunders, Peter J Hoskin, Anwar R Padhani.   

Abstract

Institutional review board approval and informed consent were obtained for this study. The aim of the study was to prospectively assess, in patients with lung cancer, the reproducibility of a quantitative whole tumor perfusion computed tomographic (CT) technique. Paired CT studies were performed in 10 patients (eight men, two women; mean age, 66 years) with lung cancer. Whole tumor permeability and blood volume were measured, and reproducibility was evaluated by using Bland-Altman statistics. Coefficient of variation of 9.49% for permeability and 26.31% for blood volume and inter- and intraobserver variability ranging between 3.30% and 6.34% indicate reliable assessment with this whole tumor technique. (c) RSNA, 2006.

Entities:  

Mesh:

Year:  2006        PMID: 16543594     DOI: 10.1148/radiol.2392050568

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  35 in total

1.  The role of magnetic resonance imaging in oncology.

Authors:  Concepción González Hernando; Laura Esteban; Teresa Cañas; Enrique Van den Brule; Miguel Pastrana
Journal:  Clin Transl Oncol       Date:  2010-09       Impact factor: 3.405

Review 2.  Imaging techniques for tumour delineation and heterogeneity quantification of lung cancer: overview of current possibilities.

Authors:  Wouter van Elmpt; Catharina M L Zegers; Marco Das; Dirk De Ruysscher
Journal:  J Thorac Dis       Date:  2014-04       Impact factor: 2.895

3.  Dynamic contrast-enhanced CT in suspected lung cancer: quantitative results.

Authors:  S W Harders; H H Madsen; H M Nellemann; T R Rasmussen; J Thygesen; H Hager; N T Andersen; F Rasmussen
Journal:  Br J Radiol       Date:  2013-09-12       Impact factor: 3.039

4.  Renal perfusion and hemodynamics: accurate in vivo determination at CT with a 10-fold decrease in radiation dose and HYPR noise reduction.

Authors:  Xin Liu; Andrew N Primak; James D Krier; Lifeng Yu; Lilach O Lerman; Cynthia H McCollough
Journal:  Radiology       Date:  2009-10       Impact factor: 11.105

5.  Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?

Authors:  Joline S W Lind; Martijn R Meijerink; Anne-Marie C Dingemans; Cornelis van Kuijk; Michel C Ollers; Dirk de Ruysscher; Pieter E Postmus; Egbert F Smit
Journal:  Eur Radiol       Date:  2010-07-13       Impact factor: 5.315

6.  Use of patient outcome endpoints to identify the best functional CT imaging parameters in metastatic renal cell carcinoma patients.

Authors:  Jill Rachel Mains; Frede Donskov; Erik Morre Pedersen; Hans Henrik Torp Madsen; Jesper Thygesen; Kennet Thorup; Finn Rasmussen
Journal:  Br J Radiol       Date:  2018-01-02       Impact factor: 3.039

Review 7.  Contrast-enhanced CT- and MRI-based perfusion assessment for pulmonary diseases: basics and clinical applications.

Authors:  Yoshiharu Ohno; Hisanobu Koyama; Ho Yun Lee; Sachiko Miura; Takeshi Yoshikawa; Kazuro Sugimura
Journal:  Diagn Interv Radiol       Date:  2016 Sep-Oct       Impact factor: 2.630

8.  Correlation of histological findings from a large ciliochoroidal melanoma with CT perfusion and 3T MRI dynamic enhancement studies.

Authors:  Jose S Pulido; Norbert G Campeau; Ernst Klotz; Andrew N Primak; Osama Saba; Kaan Gunduz; Herbert Cantrill; Diva Salomão; Cynthia H McCollough
Journal:  Clin Ophthalmol       Date:  2008-06

Review 9.  CT perfusion in oncology: how to do it.

Authors:  G Petralia; L Bonello; S Viotti; L Preda; G d'Andrea; M Bellomi
Journal:  Cancer Imaging       Date:  2010-02-11       Impact factor: 3.909

10.  Can perfusion CT assessment of primary colorectal adenocarcinoma blood flow at staging predict for subsequent metastatic disease? A pilot study.

Authors:  Vicky Goh; Steve Halligan; David M Wellsted; Clive I Bartram
Journal:  Eur Radiol       Date:  2008-08-15       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.